An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Trial Profile

An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 04 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Aug 2013 Planned End Date changed from 1 Oct 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 12 Aug 2013 Planned number of patients changed from 96 to 111 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top